HOME » News & Media

    Vyome Therapeutics Presents Positive Results from Two Key Clinical Trials at the 2019 Society for Investigative Dermatology Annual Meeting

    13 May 2019

    Vyome Therapeutics, today presented positive results from two clinical trials testing its lead anti-...

    View More
    Vyome Therapeutics to Present Clinical Data on VB-1953 at the 2019 Society for Investigative Dermatology Annual Meeting

    07 May 2019

    Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for...

    View More
    Vyome Therapeutics Begins Dosing in Phase 2 Trial of VB-1953 in Moderate to Severe Inflammatory Acne Vulgaris

    23 Apr 2019

    Vyome Therapeutics announced that it has dosed the first patient in its Phase 2 trial of the Company...

    View More
    Companies To Watch: Vyome Therapeutics

    01 Apr 2019

    Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance...

    View More
    Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

    11 Feb 2019

    Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Inve...

    View More
    Vyome advancing first-in-class acne drug with $22M financing

    23 Jan 2019

    Vyome Therapeutics Inc. has announced a $22 million financing for the phase IIb trial of its lead mo...

    View More
    Vyome Therapeutics raises $22M funding led by Iron Pillar

    04 Jan 2019

    Vyome Therapeutics' lead product, which targets the drug-resistant acne market, received approval of...

    View More
    Vyome raises $22M to advance dermatology pipeline

    03 Jan 2019

    Proceeds to finance phase 2b clinical trial for a drug with novel mechanism of action against modera...

    View More

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.